Insights into therapy: tryptophan oxidation and HIV infection.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20484729.
- Also identified by DOI 10.1126/scitranslmed.3001082.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
New data from Favre and colleagues strengthen the link between activation of the tryptophan oxidation (TOx) pathway--via the indoleamine 2,3-dioxygenase enzymes IDO1 and IDO2--and chronic inflammation in progressive HIV disease. It can now be appreciated that a pathogenic TOx activation cycle exists in HIV. TOx regulation is a therapeutic target for other diseases, such as cancer and autoimmune disorders. Here TOx control is examined with an eye to eventual therapeutic intervention in HIV disease.
Medical subject headings
- Antiviral Agents
- HIV Infections
- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Inflammation
- Tryptophan